Schroder Investment Management Group Reduces Holdings in Humana Inc. (NYSE:HUM)

Schroder Investment Management Group reduced its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 16.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,882 shares of the insurance provider's stock after selling 6,094 shares during the period. Schroder Investment Management Group's holdings in Humana were worth $7,825,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Allianz SE purchased a new stake in shares of Humana in the 4th quarter worth approximately $3,549,000. Allstate Corp bought a new stake in shares of Humana in the 4th quarter worth about $905,000. Orion Portfolio Solutions LLC raised its holdings in Humana by 3.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider's stock valued at $1,226,000 after buying an additional 171 shares during the period. denkapparat Operations GmbH purchased a new position in shares of Humana during the fourth quarter valued at approximately $323,000. Finally, Pictet Asset Management Holding SA grew its stake in Humana by 18.8% in the 4th quarter. Pictet Asset Management Holding SA now owns 72,803 shares of the insurance provider's stock worth $18,471,000 after acquiring an additional 11,523 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM stock traded up $3.35 during trading on Wednesday, hitting $285.30. The company had a trading volume of 2,653,232 shares, compared to its average volume of 1,743,722. The stock has a market capitalization of $34.43 billion, a price-to-earnings ratio of 28.67, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The stock's 50-day moving average is $265.60 and its two-hundred day moving average is $270.92.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.24%. Humana's dividend payout ratio is presently 35.58%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HUM. Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. StockNews.com upgraded shares of Humana from a "hold" rating to a "buy" rating in a report on Monday. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Morgan Stanley reduced their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Finally, Truist Financial lifted their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $284.25.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.